

Patent  
100848.213102US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231

Inventor: **R. Tam**

Serial No: **09/624855**

Filed: **July 25, 2000**

For: **Specific Modulation of TH1/TH2  
Cytokine Expression by Ribavirin in  
Activated T-Lymphocytes**

Examiner: **H. Owens**

Art Unit: **1623**

RECEIVED  
TECH CENTER 1870/2900  
03 JAN 27 AM 10:26

**AMENDMENT**

The Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

02/12/2003 RHARHON 00000010.09624855  
Dear Sir:

01 FC:1204 168.00 OP

This paper responds to the Office Action dated October 1, 2002.

**IN THE CLAIMS**

A clean listing of all pending claims following amendment herein is set forth below.

1. A method of modulating Type 1 and Type 2 response in activated T cells of a human patient comprising administering ribavirin to the T cells in a dosage to promote the Type 1 response and suppress the Type 2 response.
2. The method of claim 1 wherein the amount of ribavirin added provides a concentration of about 0.25 - 6.7 µg/ml in a medium supporting the lymphocytes.
3. A method of treating a patient having a disease which includes a viral component and a non-viral component, the non-viral component being characterized by reduced Type 1 levels and increased Type 2 levels in activated T-lymphocytes, comprising administering